IH, Brain Health, and T2D

Summary

The purpose of this study is to use a randomized, placebo-controlled study design to rigorously examine the therapeutic potential of intermittent hypoxia (IH) for improving cerebrovascular health in older adults with and without type 2 diabetes mellitus (T2DM).

Eligibility

For 30 patients with documented Type 2 diabetes

Inclusion Criteria:

* Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
* Age is \> or = 60 and \< or = 85 years of age
* Documented Type 2 diabetes
* Scoring 26 or higher on the MoCA test

Exclusion criteria:

* diagnosis of type 2 diabetes \< 1 year prior to enrollment
* HbA1c \<6.5% or \>10.0%
* body mass index \> 40 kg/m 2
* incident cardiovascular events in the last year (heart attack, stroke)
* symptomatic coronary artery disease and/or heart failure
* uncontrolled hypertension
* obstructive sleep apnea
* pulmonary disease
* dementia
* renal impairment with creatinine clearance (eGFR) of \<60 ml/min
* smoking or history of smoking within past one year

  30 nondiabetic control subjects will also be studied.

Inclusion criteria:

* Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
* Age is \> or = 60 and \< or = 85 years of age
* Scoring 26 or higher on the MoCA test

Exclusion criteria:

* Diagnosis of diabetes (Type 1 or Type 2)
* body mass index \> 40 kg/m2
* incident cardiovascular events in the last year (heart attack, stroke)
* symptomatic coronary artery disease and/or heart failure
* uncontrolled hypertension
* obstructive sleep apnea
* pulmonary disease
* dementia
* renal impairment with creatinine clearance (eGFR) of \<60 ml/min
* smoking or history of smoking within past one year

Conditions3

Locations1 site

Browse More Trials